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Designer Gene Therapy Using an Escherichia coli
Purine Nucleoside Phosphorylase/Prodrug System
and nonproliferating cells, to maintain effectiveness
against slow-growth tumor cells.
An example of the method is the herpes simplex virus
Eric M. Bennett,1 Ruchi Anand,1 Paula W. Allan,2
Abdalla E.A. Hassan,2 Jeong S. Hong,3
Dana N. Levasseur,5 David T. McPherson,3
William B. Parker,2 John A. Secrist III,2 thymidine kinase (HSV-TK)/ganciclovir combination [2],
which has been studied in numerous clinical trials [3].Eric J. Sorscher,4 Tim M. Townes,5
William R. Waud,2 and Steven E. Ealick1,* In the treatment of herpes, infected cells always express
HSV-TK, and ganciclovir is not a substrate for any mam-1Department of Chemistry and Chemical Biology
Cornell University malian kinase. However, the effectiveness of the HSV-
TK method for the treatment of tumors is limited by theIthaca, New York 14853
2Southern Research Institute difficulty of expressing the gene in a sufficient number
of cells, by low bystander activity requiring cell-to-cellBirmingham, Alabama 35205
3Department of Cell Biology contact, and by the lack of activity of the drug ganciclovir
triphosphate against nonreplicating cells [4–8].4Department of Medicine
5 Department of Biochemistry and Molecular We have applied molecular design and enzyme rede-
sign ([9–14]; reviewed [15, 16]) to Escherichia coli purineGenetics
University of Alabama at Birmingham nucleoside phosphorylase (PNP) and its natural sub-
strates to create an enzyme/prodrug combination thatBirmingham, Alabama 35294
meets the four criteria listed above for effective gene
therapy. PNP catalyzes the reversible phosphorolysis
of purine nucleosides or 2-deoxynucleosides to the freeSummary
base and sugar phosphate. Human PNP, a homotrimeric
enzyme with a total molecular weight of about 100 kDa,Activation of prodrugs by Escherichia coli purine nu-
is specific for 6-oxopurine nucleosides and has poorcleoside phosphorylase (PNP) provides a method for
activity with 6-aminopurine nucleosides [17]. In contrast,selectively killing tumor cells expressing a transfected
E. coli PNP is a homohexameric enzyme with a totalPNP gene. This gene therapy approach requires match-
molecular weight of about 150 kDa. Differences in theing a prodrug and a known enzymatic activity present
active site (Figure 1A) allow E. coli PNP to accept purineonly in tumor cells. The specificity of the method relies
nucleosides with 6-oxo, 6-amino, and some nonstan-on avoiding prodrug cleavage by enzymes already
dard 6-substituents [18] and also permit it to activatepresent in the host cells or the intestinal flora. Using
prodrugs that are not substrates for the human enzyme.crystallographic and computer modeling methods as
Systemic treatment with relatively nontoxic adenosineguides, we have redesigned E. coli PNP to cleave new
analogs, such as 9-(2-deoxy--D-ribofuranosyl)-6-meth-prodrug substrates more efficiently than does the
ylpurine (MeP-dR; Figure 1B), has resulted in the selec-wild-type enzyme. In particular, the M64V PNP mutant
tive in vivo killing of ovarian, CNS, hepatoma, and pros-cleaves 9-(6-deoxy--L-talofuranosyl)-6-methylpurine
tate tumors transfected with the E. coli PNP genewith a kcat/Km over 100 times greater than for native E.
[19–24]. The liberated base 6-methylpurine (MeP) iscoli PNP. In a xenograft tumor experiment, this com-
highly cytotoxic as a result of its conversion to the nucle-pound caused regression of tumors expressing the
oside 5-monophosphate by adenine phosphoribosyl-M64V PNP gene.
transferase. Because MeP can pass through cell mem-
branes, transfecting as few as 1% of the tumor cells
Introduction results in complete bystander killing of nearby tumor
cells in culture [25, 26]. However, previous in vivo studies
Enzyme-activating prodrug therapy is a recent approach were limited by the maximally tolerated dose (MTD) of
to the treatment of solid tumors [1]. The gene for a MeP-dR that could be administered. Our studies (our
drug-activating enzyme is selectively inserted into tumor unpublished data) indicate that MeP-dR is cleaved by
cells, and a nontoxic prodrug substrate for the enzyme intestinal prokaryotic nucleoside phosphorylases (Fig-
is administered to the patient. Cleavage of the prodrug ure 2A), increasing the toxicity of this agent: in a study
at the tumor site generates high local concentrations of Black Swiss mice with normal intestinal flora and
of a toxic drug, which kills tumor cells. For maximum mice rendered germ free in Trexler isolators [27–29],
effectiveness, the enzyme/prodrug combination should administration of a known lethal dose (300 mg/kg, QD
(a) be specific, so that the prodrug is not a substrate 3) of MeP-dR resulted in the death within 6 days of the
for naturally occurring host enzymes and is cleaved only animals with normal intestinal flora, while two animals
at the tumor site; (b) use a nontoxic prodrug that can that had been rendered germ free showed no weight
be given in high doses without serious side effects; (c) loss or other ill effects of the test compound and lived
generate a drug which can cross cell membranes to kill for 5 months before being sacrificed. In a second experi-
neighboring cells, which did not take up or express the ment, mice received 2 weeks of treatment with neomy-
gene (“bystander activity”); and (d) kill both proliferating cin, streptomycin, bacitracin, and pimaricin to reduce
intestinal bacteria and were then challenged with MeP-
dR. The LD10 of MeP-dR in antibiotic-treated animals*Correspondence: see3@cornell.edu
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Figure 1. Nucleosides and Their Interaction
with the PNP Active Site
(A) Active site structures for E. coli PNP and
human PNP. Each active site is composed of
eight segments. For each segment, the top
line, in red, gives the human PNP residue
numbers. The bottom line, in green, gives the
E. coli PNP residue numbers. Segment eight
in human PNP comes from an adjacent mono-
mer, and segments two and eight in E. coli
PNP come from an adjacent monomer (de-
noted by asterisks). The amino acid residues
are aligned based on the structures of the
two enzymes. The differences in active site
residues result in different substrate specific-
ity, even though the overall fold is the same.
(B) Modified nucleosides used in this study.
1, 9-(2-deoxy--D-ribofuranosyl)-6-methyl-
purine (MeP-dR); 2, 9-(6-deoxy--L-talofura-
nosyl)-6-methylpurine [Me(talo)-MeP-R]; 3,
9-(6-deoxy--D-allofuranosyl)-6-methylpu-
rine [Me(allo)-MeP-R]; 4, 9--L-lyxofuranosyl-
adenine (lyxo-Ado); 5, 9-(5-5-di-C-methyl-
-D-ribofuranosyl)-6-methylpurine (5,5-
dimethyl-MeP-R).
Figure 2. Schematic Representation of Tumor Treatment Using Engineered E. coli PNP
Nucleoside prodrugs are relatively nontoxic until activated by cleavage to liberate the free base. Neither of the prodrugs shown is cleaved
by human PNP.
(A) The original prodrug (shown in red) is cleaved by wild-type PNP. Because wild-type PNP is present in intestinal flora in addition to
transfected tumor cells, cancer treatment using the original prodrug results in systemic toxicity.
(B) The redesigned prodrug (shown in green) is only cleaved by the M64V mutant, thus resulting in cytotoxicity only at the site of the tumor.
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10-fold relative to wild-type PNP. The catalytic efficiencyTable 1. Specific Activities of Wild-Type and Mutant PNPs
(kcat/Km) with Me(talo)-MeP-R increased by approxi-Specific Activity
mately 140-fold relative to the wild-type enzyme andSubstrate Enzyme (nmol/mg/hr)
achieved approximately 10% of the catalytic efficiency
MeP-dR wild-type 740,000 of MeP-dR with the wild-type enzyme. This level of acti-
M64A 11,000
vation was well above the target threshold of MeP libera-M64I 190
tion previously defined as required for in vivo tumorM64Q 5100
regressions [22]. The catalytic efficiency of M64V withM64V 400,000
lyxo-Ado wild-type 4500 MeP-dR decreased only a small amount relative to wild-
M64V 43,000 type PNP. The almost 2-fold increase in Vmax was offset
Me(talo)-MeP-R wild-type 960 by a 3-fold increase in Km. Although M64V PNP cleaved
M64A 1800
Me(allo)-MeP-R 2-fold faster than wild-type enzyme, thisM64I 20
rate was only 0.4% the rate of cleavage of Me(talo)-M64Q 90
MeP-R with this mutant enzyme.M64V 68,000
Me(allo)-MeP-R wild-type 110
M64V 240 Computer Modeling
5,5-dimethyl-MeP-R wild-type no activity detected We inspected the lowest-energy conformations found
M64V 280
for each complex and characterized the lowest-energy
structure that best satisfied requirements for catalysis.
The structures chosen by applying these criteria were
(490 mg/kg, QD  3) was approximately 5-fold higher the global minima in all enzyme/ligand pairings where
than it was in nontreated animals. Therefore, to alleviate the ligand was a good substrate and were not the global
the toxicity caused by intestinal bacteria, we have rede- minima for pairings where the ligand was a poor sub-
signed E. coli PNP and its prodrug substrate to create strate.
a new combination, M64V mutant PNP with 9-(6-deoxy- In the wild-type enzyme models with Me(allo)-MeP-R
-L-talofuranosyl)-6-methylpurine [Me(talo)-MeP-R; Fig- and Me(talo)-MeP-R, the global minimum was not the
ure 1B], in which the prodrug is cleaved only by the most favorable conformation for catalysis. In the latter
enzyme to be delivered to the tumor (Figure 2B). case, the sugar atoms moved (likely due to steric inter-
ference as shown in Figures 3A and 3B) by 1.0–1.8 A˚ in
the plane of the sugar toward the phosphate. The O5Results
atom pointed toward the Phe159 phenyl ring and did
not form the hydrogen bond with His4 seen for otherKinetic Measurements
Assays with M64A, M64I, M64Q, and M64V mutant E. substrates. For Me(allo)-MeP-R, the situation was simi-
lar, but the sugar atom movements ranged from 1.0–coli PNPs showed MeP-dR cleavage at less than 2% of
the wild-type activity, except M64V, for which the rela- 2.7 A˚, and the stereochemistry change at C5 caused
the O5 atom to hydrogen bond with Ser90. Higher-tive rate was 50%. Me(talo)-MeP-R activities with
M64A, M64I, M64Q, and M64V mutants were 200%, 2%, energy Me(allo)-MeP-R structures (11.5 kJ/mol or more
above the global minimum) conformed more closely to10%, and 7000% of wild-type activity, respectively.
M64V PNP was also more active than wild-type PNP catalytic constraints but showed O2 and O3 making
strong hydrogen bonds to the phosphate, with a weakerwith other 5-modified nucleoside analogs, including
9-(6-deoxy--D-allofuranosyl)-6-methylpurine [Me(allo)- O2-E181 hydrogen bond and no O3-E181 hydrogen
bond (good riboside substrates typically have O2 andMeP-R, Figure 1B, factor of 2 more active], 9--L-lyxo-
furanosyl-adenine (lyxo-Ado, Figure 1B, factor of 9), and O3 hydrogen bonds to E181). The O5-His4 interaction
was still missing. Some wild-type/Me(talo)-MeP-R con-9-(5-5-di-C-methyl--D-ribofuranosyl)-6-methylpurine
(5,5-dimethyl-MeP-R, Figure 1B, activity became de- formations showed geometry almost identical to inosine
but had energies of at least 5.7 kJ/mol above the globaltectable). Specific activities are summarized in Table 1.
Because Me(talo)-MeP-R and lyxo-Ado had the great- minimum.
In the M64V/Me(talo)-MeP-R model, the methyl group,est activity with M64V PNP, kinetic parameters were
determined with these compounds (Table 2). For both which replaces MeP-dR’s pro-S hydrogen on the C5
carbon atom, occupied a hydrophobic hole created bysubstrates, Km decreased and Vmax increased by about
Table 2. Kinetic Values with Wild-Type and Mutant PNPs
Vmax
Substrate Enzyme Km (M) (nmol mg1 hr1) Vmax/Km kcat (min1) kcat /Km
MeP-dR wild-type 126 1,460,000 11,400 580 4.6
M64V 340 2,480,000 7400 990 2.9
Me(talo)-MeP-R wild-type 3000 20,400 7 8 0.0027
M64V 250 240,000 957 96 0.38
lyxo-Ado wild-type 1350 38,400 28 16 0.012
M64V 210 276,000 877 74 0.35
Each value represents the average of at least two separate measurements.
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Figure 3. Redesign of PNP to Accommodate a New Prodrug
(A) Modeling studies predicted a steric clash (shown in green) between the 5-methyl group of Me(talo)-MeP-R and the side chain of Met64.
(B) Stereodiagram of the MeP-dR/wild-type PNP crystal structure (our unpublished data), with crystal structure carbon atoms shown in green.
Modeling an additional carbon atom (shown in black) on C5 results in unfavorable steric interactions (purple dotted lines) with the Met64
side chain.
(C) The unfavorable interaction is eliminated in the M64V PNP.
(D) Crystal structure of Me(talo)-MeP-R with M64V PNP, with the global minimum from computational docking overlayed in black wire frame
representation. Panels (B) and (D) were created with Molscript [48] and Raster3D [49].
the M64V mutation (Figures 3C and 3D) and bordered displacements from the standard base binding position.
The M64V complexes showed Fo  Fc density for theby Phe159, Val64, and Ile71. However, replacing the
pro-R hydrogen to generate Me(allo)-MeP-R did not fill base at 3.0–3.5  and for the sugar in the range 2.0–3.0 .
Comparison of the M64V/Me(talo)-MeP-R structurethis hole unless the ligand changed conformation. Most
of the low-energy structures either showed a C1-exo (Figure 3B) with that of the wild-type/inosine complex
revealed rms differences of 0.53 A˚ for the base andsugar pucker or showed the C5-hydroxyl pointing to-
ward the Phe159 phenyl ring rather than His4. A few 0.28 A˚ for the sugar. Slight movements of the base and
Asp204 increased the Asp204/N7 interaction distanceconformations had appropriate geometry for catalysis
but were higher in energy (8.4 kJ/mol or more above the to 3.5 A˚ in the A monomer, with a similar conformation
in the C monomer. In the B monomer there was noglobal minimum). These structures were similar to the
Me(talo)-MeP-R global minimum except for the reversed density for the Asp204 side chain. The A monomer had
no phosphate bound, and the loop from residues 18stereochemistry, which caused the C5-OH to approach
His4 from inside the hydrophobic hole, while the C6 to 25 changed conformation to occupy the phosphate
binding site.methyl group was exposed to solvent.
In the M64V/Me(allo)-MeP-R complex, the nucleoside
moved away from Glu181, breaking the O2 and O3X-Ray Crystallography
Data collection and refinement statistics appear in Table hydrogen bonds to Glu181. The movement was in the
plane of the Glu181 carboxylate, such that the nucleo-3. PNP crystallizes with three monomers (designated A,
B, and C) per asymmetric unit. Superposition of empty side was not bound as deeply in the active site. The
displacements were largest (2.0 A˚ and 3.3 A˚ for O2M64V PNP and wild-type E. coli PNP [30] showed no
significant folding differences. The active sites of the and O3) in the A and B monomers and smaller (1.4 A˚
and 1.8 A˚) in the C monomer. The O5 to His4 hydrogenwild-type/Me(talo)-MeP-R and wild-type/Me(allo)-MeP-R
complexes had no major protein conformational changes bond was only observed in the C monomer.
In the M64V/MeP-dR structure, ligand binding in the Band showed density only for the base, with moderate
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Table 3. Summary of Data Processing and Refinement Statistics
Enzyme  Compound M64V M64V  MeP-dR M64V  talo Native  talo M64V  allo Native  allo
Refinement resolution (A˚) 25–2.7 25–2.2 25–2.3 25–2.5 25–2.4 25–2.5
Unique reflections 28,781 52,262 47,047 37,511 41,133 36,116
Redundancy 10.3 4.3 9.5 8.5 10.0 8.7
Completenessa 100 (100) 98.8 (98.7) 100 (100) 100 (100) 100 (100) 100 (100)
Rsym (%)a 10.0 (22.2) 8.7 (28.7) 10.0 (30.1) 7.6 (26.4) 11.0 (33.2) 7.4 (21.7)
I/a 6.2 (3.3) 6.5 (2.2) 5.7 (2.4) 7.7 (2.7) 4.5 (2.1) 7.9 (3.3)
R factor (%) 20.6 23.2 22.9 21.5 23.0 21.3
Rfree (%) 25.1 25.6 25.9 24.5 25.8 24.4
Nonhydrogen atoms 5582 5672 5643 5591 5636 5598
Bond rms deviation (A˚) 0.007 0.005 0.007 0.007 0.006 0.006
Angle rms deviation (	) 1.38 1.25 1.34 1.35 1.35 1.35
Avg protein B factor (A˚2) 23.0 26.8 25.9 33.4 24.5 29.7
Avg nucleoside B factor (A˚2) NA 26.3 35.9 65.7b 36.7 49.9b
a Values for the highest resolution shell are given in parentheses.
b Only the purine base was modeled for this complex.
monomer was roughly identical to the binding of inosine in the ribose ring were inactive as substrates for E. coli
PNP (
500,000-fold reduction in activity relative to MeP-(base rms 0.54 A˚, sugar rms 0.28 A˚) but with a distance
of 3.4 A˚ between N7 and Asp204 and with a slight change dR). Of the nucleosides that were cleaved, Me(talo)-
MeP-R showed reduced but still significant activityin sugar pucker to O4-exo. The A monomer showed
significant rms movements of 2.2 A˚ for the sugar and (0.2%) compared to MeP-dR itself. Using the structure
of the PNP/MeP-dR complex (our unpublished data) as2.4 A˚ for the base. The nucleoside moved, with O5
as the approximate pivot point, toward a hydrophobic a template, Me(talo)-MeP-R was manually modeled into
the active site. Examination of the model suggestedpocket formed by Ala156, Phe159, Tyr160, and Phe167.
The C1-phosphate distance increased to 5 A˚ as a result. that the loss of activity resulted from close contact be-
tween the C6 of Me(talo)-MeP-R and the side chain ofThe sugar adopted a C3-endo pucker. The motion in
the C monomer was different and smaller in magnitude, Met64 (Figures 3A and 3B). To relieve the contact, we
modeled other amino acid side chains in place of Met64,with the MeP-dR C8 atom moving to the position of the
inosine N7 atom and the sugar moving toward Ser90 by and several appeared to create the required space for
the additional methyl group (Figures 3C and 3D). Of0.7 A˚. The sugar adopted a C2-exo pucker. In the A
monomer, movement of the base broke the hydrogen the experimentally tested mutants, M64V showed the
highest increase (100-fold) in processing of Me(talo)-bond, and a water molecule hydrogen bonded to both
the base N7 (3.0 A˚) and Asp 204 (2.6 A˚). A hydrogen MeP-R (Table 1). To further characterize this enzyme/
prodrug system, we used crystallography and computerbond between the O5 oxygen of the sugar and His4
was observed in all three monomers. modeling to determine the structures of MeP-dR,
Me(talo)-MeP-R, and Me(allo)-MeP-R (with the oppo-In all complexes, the loop region from residue 205 to
220 showed varying disorder for all three monomers. site stereochemistry at C5) bound to M64V and wild-
type PNP.
The results showed that MeP-dR adopts a conforma-Biological Studies
tion similar to that of normal purine nucleoside sub-The MTD for Me(talo)-MeP-R, defined as the maximal
strates when bound to PNP, with the largest differencedose of a compound that causes less than 15% weight
being a change in sugar pucker from C4-endo to O4-loss and no deaths in mice when administered with a
exo. The pucker plays a key role in catalysis: if the sugarparticular route and schedule, was found to be 400 mg/
C1 atom is above the plane defined by C2, O4, andkg/day given ip (intraperitoneally) for 3 consecutive
C4, then, as the glycosidic bond lengthens during for-days. D54 cells transfected with the M64V gene were
mation of the proposed oxocarbenium intermediate, thekilled with concentrations of Me(talo)-MeP-R as low as
C1 atom moves into the C2-O4-C4 plane, satisfying20 M (Figure 4A). Treatment of mice bearing D54 tu-
the oxocarbenium planarity requirement. If C1 is in ormors that express M64V showed tumor regression for
below the plane, lengthening of the glycosidic bondat least 60 days when treated with Me(talo)-MeP-R on
conflicts with creating a planar intermediate. The good3 consecutive days (Figure 4B).
substrates inosine, adenosine, and MeP-dR all adopt
puckers (C4-endo and O4-exo) fulfilling this require-Discussion
ment, while 9--D-xylofuranosyladenine, which binds to
PNP but is not cleaved, adopts a pucker (C3-exo), whichBecause intestinal bacteria appear to contribute to the
does not (our unpublished data). Xylosides maintain O2toxicity of MeP-dR, the major goal of this research was
and O3 hydrogen bonds to Glu181 as seen in ribosideto create an antitumor prodrug cleaved only by an engi-
substrates but at the price of a catalytically unfavorableneered PNP and not by enzymes naturally occurring in
pucker.the host or the intestinal flora. Numerous nucleoside
In contrast to MeP-dR, ligand electron density foranalogs have been screened against the wild-type en-
zyme [31], and many of the analogs with modifications the wild-type/Me(talo)-MeP-R complex was disordered,
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Figure 4. Biological Activity of Me(talo)-MeP-R
(A) In vitro cellular activity. The dark stain indicates live cells on the plate, and the clear wells indicate elimination of the cell population. Even
at the highest concentration of the compound used (400 mM), parental D54 cells did not exhibit cell death. However, D54-M64V PNP cells
died at every concentration of drug tested.
(B) In vivo activity of Me(talo)-MeP-R against D54 tumors that express M64V. Mice were treated (ip) with saline (closed circles), 100 mg/kg
Me(talo)-MeP-R given once a day for 3 days (open circles), or 20 mg/kg of Me(talo)-MeP-R given 5 times per day (every 2 hr) for 3 days
(closed triangles).
presumably owing to close contacts between C6 and MeP-R and M64V PNP to kill cells in vitro and in vivo.
The prodrug demonstrated poor cytotoxicity againstMet64. Density was only observed in the base binding
site. Computer modeling showed that the lowest-energy nine non-PNP-transduced human tumor cell lines. The
concentration of compound required to inhibit cellbinding conformations failed to meet one or more criteria
for catalysis. Conversely, modeling and crystallography growth by 50% was greater than 200 M in all cases.
However, in D54 cells transfected with M64V, Me(talo)-both showed that the M64V mutation created a hy-
drophobic pocket, bordered by Phe159, Val64, and MeP-R was able to kill the cells at concentrations as
low as 20 M (Figure 4A). The MTD of Me(talo)-MeP-RIle71, that accommodated C6, with ligand conforma-
tional parameters similar to those seen for other good was approximately 400 mg/kg/day (given ip on 3 con-
secutive days), which was four times greater than thesubstrates (Figure 3D). The stereochemistry at the C5
carbon was critical: the M64V/Me(allo)-MeP-R crystal MTD of MeP-dR (100 mg/kg/day given ip on 3 consecu-
tive days). The difference in the MTD between these twostructure showed significantly different binding confor-
mations for the sugar, in which the C1 atom was 4.4 A˚ compounds (4-fold) was less than the differences in their
catalytic rates with the wild-type enzyme (about 1000-from the nearest phosphate oxygen (too far for effective
phosphorolysis) and the C5-OH moved to form a hydro- fold), which suggested Me(talo)-MeP-R has some other
activity in vivo that results in toxicity and limits thegen bond with Ser90 rather than His4.
We carried out initial tests of the ability of Me(talo)- amount of compound that could be administered to
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bohydrate [32–34]. Lyxo-Ado and MeP-dR were prepared as de-mice. Treatment of mice bearing D54 tumors that stably
scribed [35–37].express M64V with Me(talo)-MeP-R resulted in excellent
antitumor activity (Figure 4B). The maximally tolerated
Kinetic Datadose of Me(talo)-MeP-R was less in animals bearing D54
Enzyme activity was measured in 200 L volumes containing 50tumors that express M64V than it was in non-tumor-
mM potassium phosphate (pH 7.4), various concentrations of nucle-bearing animals. All tumors regressed after 3 days of
oside, and enough enzyme to give a linear increase in product forma-
treatment with Me(talo)-MeP-R. These results indicate tion during incubation at 25	C. The reaction was stopped by boiling,
that M64V expressed in vivo is able to cleave Me(talo)- and the products were separated from substrate as described [23].
Michaelis-Menten parameters were determined from double-recip-MeP-R to generate MeP in the tumor cells and cause
rocal plots of 1/velocity versus 1/[substrate]. The best line was deter-their death.
mined by linear regression of at least five datum points (regressionWe have shown that enzyme redesign can be used
coefficients were greater than 0.97).to control prodrug activation by nucleoside phosphory-
lases. This new enzyme/prodrug combination is directly
Computer Modelingapplicable in a gene therapy approach to tumor cell
Docking studies of MeP-dR, Me(allo)-MeP-R, and Me(talo)-MeP-R
killing and is the first step in the optimization of the with native and M64V PNP used the GB/SA solvation model [38] and
PNP strategy for the treatment of cancer. Further in vivo AMBER* force field as implemented in version 7.2 of the program
studies will be needed to fully evaluate the usefulness MacroModel [39]. Several generalized ligand angle parameters were
adjusted using quantum mechanics calculations at the 6-31G** (ge-of Me(talo)MeP-R against tumors that express the M64V
ometry optimization) and LMP2/cc-pvtz(-f) (single point energies)gene. It is likely that additional improvements will be
levels.realized after further cycles of design, analysis, and opti-
Simulations were based on the structure of the wild-type enzyme
mization of treatment. complex with inosine (our unpublished results) using a 14 A˚ shell
around the active site. Each nucleoside was positioned in a nonstan-
dard conformation in the binding site and conformational searching
Significance was performed using the l-LMOD [40] and MCMM [41] methods to
generate trial structures. Residues 4, 64, 90, 159, 180, 203, 204, the
ligand, and the phosphate were allowed to move freely, while allEnzyme-activating prodrug therapy is a promising ap-
other atoms were frozen. The torsions selected for MCMM wereproach to the treatment of solid tumors. A gene encod-
C  C and C  S of Met64 and Met180, C  C of Asp204, anding an enzyme is introduced into a tumor, and the
C1-N9 and C4-C5 of the ligand. The M64V shell was constructed
patient is treated with a nontoxic prodrug, which is by manually mutating Met64 to Val. The C  C torsion of Val64
converted by the enzyme in the tumor to a toxic, tumor- was included in the MCMM torsion list.
killing drug. The strategy requires that no naturally Searching was performed until a block of at least 15,000 trial
steps resulted in no new structures within 15 kJ/mol of the globaloccurring enzymes in the host activate the prodrug
minimum. Structures were minimized to a gradient of 0.05 kJ/mol-A˚.and that the drug be able to diffuse across cell mem-
branes to kill neighboring tumor cells that failed to
Crystallizationtake up or express the gene (bystander activity). The
PNP was dialyzed into 10 mM KH2PO4 buffer at pH 8.0 and concen-herpes simplex virus thymidine kinase (HSV-TK)/gan-
trated to 35 mg/mL. Hanging drops were prepared by mixing 2 Lciclovir combination is one example of the method
of protein with 2 L 30% ammonium sulfate and 50 mM citrate
but is limited by poor bystander activity and inactivity buffer (pH 5.4). Needle-like crystals appeared within 24–48 hr at
against cells that are not dividing rapidly. Another room temperature. Wild-type and M64V PNPs crystallized in space
combination using E. coli purine nucleoside phosphor- group P6122 with approximate unit cell dimensions of a  121.6 A˚
and c  240.0 A˚. Me(talo)-MeP-R, Me(allo)-MeP-R, and MeP-dRylase with nucleoside prodrugs has shown promise,
were soaked into the crystals at concentrations of 2–5 mM for 24 hr.but the drug doses are limited by toxicity due to cleav-
age of the prodrug by bacterial nucleoside phosphory-
Data Collection and Processinglases present in the intestinal flora.
Crystals were flash-cooled under a 110 K nitrogen stream with aUsing crystallographic and computer modeling meth-
cryoprotectant solution of 20% glycerol in the mother liquor. Theods, we have redesigned E. coli purine nucleoside
data were measured at the A1 and F1 stations at the Cornell High
phosphorylase and its natural substrates to address Energy Synchrotron Source in 1	 oscillations with exposure times
the problem of prodrug activation in the digestive tract. ranging from 20 to 60 s, using a Quantum-4 CCD detector (San
Diego Area Detector Systems) with a crystal to detector distanceThe M64V enzyme mutant but not the wild-type en-
ranging from 200 to 240 mm. Data (60	 to 120	) were collectedzyme cleaves the prodrug 9-(6-deoxy--L-talofurano-
depending on beam time constraints and processed with MOSFLMsyl)-6-methylpurine to generate the toxic drug 6-meth-
[42] and SCALA [43].ylpurine, which has high bystander activity and leads
to tumor regression in a mouse model system.
Structure Determination and Refinement
The structures were solved by molecular replacement with CNS
1.0 [44] and PDB entry 1ECP [30] as a search model. Rigid bodyExperimental Procedures
refinement, simulated annealing, energy minimization, and individ-
ual B factor refinement were performed using CNS with approxi-Protein and Ligand Sources
Purified wild-type PNP was a gift from Dr. George W. Koszalka of mately 9% of the reflections reserved to calculate Rfree. Manual re-
building was performed with O [45].Wellcome Research Laboratories. Mutant PNPs (M64A, M64V, M64I,
M64Q) with a cleavable polyhistidine tail were generated using a kit Ligand density was visible with M64V mutant PNP for all three
compounds. In the wild-type complexes with Me(talo)-MeP-R andfrom Stratagene (La Jolla, California) and purified by standard nickel-
affinity techniques. Me(allo)-MeP-R, density was observed only for the purine base, but
the entire MeP-dR ligand was observed. A noncomplexed M64VMe(talo)-MeP-R, Me(allo)-MeP-R, and 5-5-dimethyl-MeP-R were
synthesized by condensing MeP with the appropriate blocked car- structure was also determined as a control.
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